-+ 0.00%
-+ 0.00%
-+ 0.00%

ULTRAGENYX PHARMA PLUNGES 45% PREMARKET AFTER CO'S RARE DISEASE DRUG FAILS TO MEET MAIN GOAL IN LATE-STAGE TRIAL

Reuters·09/03/2026 09:16:46

Please log in to view news